Related Experiment Video
Updated: Aug 5, 2025

Resolving Water, Proteins, and Lipids from In Vivo Confocal Raman Spectra of Stratum Corneum through a Chemometric Approach
Published on: September 26, 2019
Atopic dermatitis - Perspectives and unmet medical needs.
Timo Buhl1,2, Thomas Werfel3,4
1Department of Dermatology, Venereology and Allergology, University Medical Center Göttingen, Göttingen, Germany.
New research offers insights into atopic dermatitis (AD) treatments. While diagnostic biomarkers are lacking, advanced therapies like Janus kinase (JAK) inhibitors and targeted antibody treatments are becoming available for eczema.
Area of Science:
- Dermatology
- Immunology
- Pharmacology
Background:
- Atopic dermatitis (AD) is a chronic inflammatory skin condition with evolving understanding of its pathophysiology.
- Recent advancements have improved comprehension of AD, its associated conditions, and therapeutic options.
Purpose of the Study:
- To present new and practice-relevant findings from current atopic dermatitis research.
- To review diagnostic challenges and emerging therapeutic strategies for AD.
Main Methods:
- Review of recent studies on atopic dermatitis diagnosis and subtypes.
- Analysis of current and investigational therapeutic agents, including topical and systemic treatments.
- Examination of novel targets for antibody therapies.
Main Results:
- No definitive diagnostic biomarker or treatment response predictor for AD has been established.
- Janus kinase (JAK) inhibitors are nearing approval or are approved for specific eczema subtypes.
- Current systemic therapies include IL-4/13 inhibitors and oral JAK inhibitors with varying profiles.
- Promising new targets in development include IL-31, neurokinin-1 receptor, and OX40/OX40L axis inhibition.
Conclusions:
- Topical and systemic therapies, including JAK inhibitors and antibody treatments, offer new options for AD management.
- Future research should focus on primary prevention, disease progression modulation, and the impact of early intervention on comorbidities.
Related Concept Videos
Changes in Skin Color: Clinical Perspectives
Albinism
Albinism is a genetic disorder that affects (completely or partially) the coloring of skin, hair, and eyes. The defect is primarily...
Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
Asthma: Pathogenesis and Management
Asthma is classified as allergic and non-allergic. Allergens such as dust mites, pollen, and pet dander trigger allergic asthma, while factors like cold air, intense emotions, or exercise can induce non-allergic asthma.
Skin Diseases and Disorders
Gram-positive Staphylococcus spp. and Streptococcus spp. are responsible for many of the most common skin infections. However, many...
Hypersensitivities
Types of Hypersensitivities
Hypersensitivity reactions are categorized into four types: Type 1, Type 2, Type 3, and Type 4. Each type has a distinct mechanism...
Asthma-IV: Diagnostic and Management
Clinical Assessment for Asthma:
This is the first step in diagnosing and managing asthma. It includes:

